Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population
Background Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologics approved for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). We examined adherence and persistence among PsO patients wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-05-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2021.1950600 |
| _version_ | 1797683497734766592 |
|---|---|
| author | Chang Xu Amanda Teeple Bingcao Wu Timothy Fitzgerald Steven R. Feldman |
| author_facet | Chang Xu Amanda Teeple Bingcao Wu Timothy Fitzgerald Steven R. Feldman |
| author_sort | Chang Xu |
| collection | DOAJ |
| description | Background Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologics approved for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). We examined adherence and persistence among PsO patients with comorbid PsA who initiated treatment with any of these biologics. Methods Adult patients with ≥1 pharmacy/medical claim for any of these seven biologics, and ≥1 diagnosis of both PsO and PsA were selected from the MarketScan Commercial database (July 2014–June 2019). Adherence and persistence rates were examined among the seven study cohorts during fixed follow-up periods (3, 6, 9, and 12 months). Results Among patients with ≥9 months of continuous enrollment, 3,251 initiated ADA, 418 CER, 1,563 ETA, 126 GUS, 422 IXE, 1,596 SEC, and 1,267 UST. During the 9-month follow-up period, the proportions of adherent patients were numerically highest among those treated with GUS (59.5%) and UST (57.0%), followed by SEC (47.9%), IXE (47.6%), ADA (46.8%), ETA (37.4%), and CER (22.0%); persistence rates were also numerically highest among those treated with GUS (65.9%) and UST (65.7%). Limitations Adjustment for potential confounders was not conducted. Conclusions Adherence and persistence rates were numerically highest among patients who initiated GUS and UST. |
| first_indexed | 2024-03-12T00:16:18Z |
| format | Article |
| id | doaj.art-c67c4712983544fbbaf1715618e373aa |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:16:18Z |
| publishDate | 2022-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-c67c4712983544fbbaf1715618e373aa2023-09-15T14:28:51ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-05-013342270227710.1080/09546634.2021.19506001950600Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured populationChang Xu0Amanda Teeple1Bingcao Wu2Timothy Fitzgerald3Steven R. Feldman4Janssen Scientific Affairs, LLCJanssen Scientific Affairs, LLCJanssen Scientific Affairs, LLCJanssen Scientific Affairs, LLCWake Forest School of MedicineBackground Adalimumab (ADA), certolizumab pegol (CER), etanercept (ETA), guselkumab (GUS), ixekizumab (IXE), secukinumab (SEC), and ustekinumab (UST) are biologics approved for the treatment of psoriasis (PsO) and psoriatic arthritis (PsA). We examined adherence and persistence among PsO patients with comorbid PsA who initiated treatment with any of these biologics. Methods Adult patients with ≥1 pharmacy/medical claim for any of these seven biologics, and ≥1 diagnosis of both PsO and PsA were selected from the MarketScan Commercial database (July 2014–June 2019). Adherence and persistence rates were examined among the seven study cohorts during fixed follow-up periods (3, 6, 9, and 12 months). Results Among patients with ≥9 months of continuous enrollment, 3,251 initiated ADA, 418 CER, 1,563 ETA, 126 GUS, 422 IXE, 1,596 SEC, and 1,267 UST. During the 9-month follow-up period, the proportions of adherent patients were numerically highest among those treated with GUS (59.5%) and UST (57.0%), followed by SEC (47.9%), IXE (47.6%), ADA (46.8%), ETA (37.4%), and CER (22.0%); persistence rates were also numerically highest among those treated with GUS (65.9%) and UST (65.7%). Limitations Adjustment for potential confounders was not conducted. Conclusions Adherence and persistence rates were numerically highest among patients who initiated GUS and UST.http://dx.doi.org/10.1080/09546634.2021.1950600adherencebiologicspersistencepsoriasispsoriatic arthritis |
| spellingShingle | Chang Xu Amanda Teeple Bingcao Wu Timothy Fitzgerald Steven R. Feldman Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population Journal of Dermatological Treatment adherence biologics persistence psoriasis psoriatic arthritis |
| title | Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population |
| title_full | Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population |
| title_fullStr | Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population |
| title_full_unstemmed | Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population |
| title_short | Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population |
| title_sort | treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a u s commercially insured population |
| topic | adherence biologics persistence psoriasis psoriatic arthritis |
| url | http://dx.doi.org/10.1080/09546634.2021.1950600 |
| work_keys_str_mv | AT changxu treatmentadherenceandpersistenceofsevencommonlyprescribedbiologicsformoderatetoseverepsoriasisandpsoriaticarthritisinauscommerciallyinsuredpopulation AT amandateeple treatmentadherenceandpersistenceofsevencommonlyprescribedbiologicsformoderatetoseverepsoriasisandpsoriaticarthritisinauscommerciallyinsuredpopulation AT bingcaowu treatmentadherenceandpersistenceofsevencommonlyprescribedbiologicsformoderatetoseverepsoriasisandpsoriaticarthritisinauscommerciallyinsuredpopulation AT timothyfitzgerald treatmentadherenceandpersistenceofsevencommonlyprescribedbiologicsformoderatetoseverepsoriasisandpsoriaticarthritisinauscommerciallyinsuredpopulation AT stevenrfeldman treatmentadherenceandpersistenceofsevencommonlyprescribedbiologicsformoderatetoseverepsoriasisandpsoriaticarthritisinauscommerciallyinsuredpopulation |